These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 26542079)

  • 1. Toward a cure for HIV--Seeking effective therapeutic vaccine strategies.
    Autran B
    Eur J Immunol; 2015 Dec; 45(12):3215-21. PubMed ID: 26542079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune interventions in HIV infection.
    Carcelain G; Autran B
    Immunol Rev; 2013 Jul; 254(1):355-71. PubMed ID: 23772631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic vaccination against HIV: current progress and future possibilities.
    Puls RL; Emery S
    Clin Sci (Lond); 2006 Jan; 110(1):59-71. PubMed ID: 16336205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immunopathogenesis and therapeutic immunization in HIV-infection].
    Kran AM; Kvale D
    Tidsskr Nor Laegeforen; 2006 Nov; 126(23):3112-6. PubMed ID: 17160117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine and immunotherapeutic interventions.
    Pantaleo G; Lévy Y
    Curr Opin HIV AIDS; 2013 May; 8(3):236-42. PubMed ID: 23478912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic immunization strategies for the control of HIV-1.
    Dorrell L
    Expert Rev Vaccines; 2005 Aug; 4(4):513-20. PubMed ID: 16117708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune reconstitution in HIV-1-infected patients.
    Imami N; Hardy G; Pires A; Burton C; Pido-Lopez J; Mela C; Gotch F
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1138-45. PubMed ID: 12211404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic vaccines against HIV infection.
    García F; León A; Gatell JM; Plana M; Gallart T
    Hum Vaccin Immunother; 2012 May; 8(5):569-81. PubMed ID: 22634436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic HIV-1 matrix protein p17-based AT20-KLH therapeutic immunization in HIV-1-infected patients receiving antiretroviral treatment: A phase I safety and immunogenicity study.
    Iaria ML; Fiorentini S; Focà E; Zicari S; Giagulli C; Caccuri F; Francisci D; Di Perri G; Castelli F; Baldelli F; Caruso A
    Vaccine; 2014 Feb; 32(9):1072-8. PubMed ID: 24456624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-subtype gp160 DNA immunization induces broadly neutralizing anti-HIV antibodies.
    Rollman E; Hinkula J; Arteaga J; Zuber B; Kjerrström A; Liu M; Wahren B; Ljungberg K
    Gene Ther; 2004 Jul; 11(14):1146-54. PubMed ID: 15103320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted Immune Interventions for an HIV-1 Cure.
    Perreau M; Banga R; Pantaleo G
    Trends Mol Med; 2017 Oct; 23(10):945-961. PubMed ID: 28890135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic vaccines against HIV need international partnerships.
    Autran B; Debré P; Walker B; Katlama C
    Nat Rev Immunol; 2003 Jun; 3(6):503-8. PubMed ID: 12776210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A therapeutic HIV vaccine using coxsackie-HIV recombinants: a possible new strategy.
    Halim SS; Collins DN; Ramsingh AI
    AIDS Res Hum Retroviruses; 2000 Oct; 16(15):1551-8. PubMed ID: 11054268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendrimers as nonviral vectors in dendritic cell-based immunotherapies against human immunodeficiency virus: steps toward their clinical evaluation.
    Vacas-Córdoba E; Climent N; De La Mata FJ; Plana M; Gómez R; Pion M; García F; Muñoz-Fernández MÁ
    Nanomedicine (Lond); 2014 Dec; 9(17):2683-702. PubMed ID: 25529571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rethinking globally relevant vaccine strategies to human immunodeficiency virus type-1.
    Gray CM; Puren AJ
    Arch Immunol Ther Exp (Warsz); 2000; 48(4):235-41. PubMed ID: 11059639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients.
    Lévy Y; Gahéry-Ségard H; Durier C; Lascaux AS; Goujard C; Meiffrédy V; Rouzioux C; El Habib R; Beumont-Mauviel M; Guillet JG; Delfraissy JF; Aboulker JP;
    AIDS; 2005 Feb; 19(3):279-86. PubMed ID: 15718838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term persistence of vaccination and HAART to human immunodeficiency virus (HIV).
    Boström AC; Hejdeman B; Matsuda R; Fredriksson M; Fredriksson EL; Bratt G; Sandström E; Wahren B
    Vaccine; 2004 Apr; 22(13-14):1683-91. PubMed ID: 15068851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.
    Mascarell L; Fayolle C; Bauche C; Ladant D; Leclerc C
    J Virol; 2005 Aug; 79(15):9872-84. PubMed ID: 16014948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New challenges in therapeutic vaccines against HIV infection.
    Leal L; Lucero C; Gatell JM; Gallart T; Plana M; García F
    Expert Rev Vaccines; 2017 Jun; 16(6):587-600. PubMed ID: 28431490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An HIV-based lentiviral vector as HIV vaccine candidate: Immunogenic characterization.
    Lemiale F; Asefa B; Ye D; Chen C; Korokhov N; Humeau L
    Vaccine; 2010 Feb; 28(8):1952-61. PubMed ID: 20188251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.